CA-XPRIZE
9.3.2021 09:33:12 CET | Business Wire | Press release
XPRIZE , the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, in partnership with Cognizant (Nasdaq: CTSH), one of the world's leading technology and professional services companies, today announced the Grand Prize Winners in the $500K Pandemic Response Challenge . The four-month global competition was designed to harness the power of data and artificial intelligence in equipping policymakers, health officials and business leaders with the insights and guidance necessary to implement public safety measures that help keep local economies open while minimizing virus outbreaks as vaccines become more widely available. These decision-makers are encouraged to use the results, methodologies and technology from the challenge as reference on approaches to minimize potential outbreaks, now and moving forward.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005419/en/
Winning first place honors is the VALENCIA IA4COVID19 (Valencia, Spain) team, coordinated by Dr. Nuria Oliver, Commissioner of the Presidency of the Generalitat Valenciana, and J. Alberto Conejero, Director of the Applied Mathematics Department at Universitat Politècnica de València. In second place is JSI vs COVID (Ljubljana, Slovenia), coordinated by Mitja Lustrek, Head of the Ambient Intelligence Group at the Jozef Stefan Institute, whose team members were previous competitors in the Qualcomm Tricorder XPRIZE. These top-performing teams were selected from among 48 finalists in 17 countries. Both teams will share equally the total prize purse of $500,000, however judges have chosen to distinguish team VALENCIA IA4COVID19 as first place due to their exemplary submissions. In total, over 100 teams throughout the world initially joined the competition.
The Pandemic Response Challenge required teams to build effective data-driven AI systems capable of accurately predicting COVID-19 transmission rates and prescribing intervention and mitigation measures that, with testing in “what-if” scenarios, were shown to minimize infection rates as well as negative economic impacts. The winning models will be made available to policymakers, business leaders, and health officials worldwide as they consider strategies for safely reopening society and restoring the global economy.
"We are absolutely thrilled to announce the winners of the Pandemic Response Challenge, and are extremely grateful to Cognizant for their support during this competition,” said Amir Banifatemi, Chief Innovation and Growth Officer of XPRIZE. “This month marks a year since the beginning of the COVID-19 outbreak globally, and since then we have sought out various ways in which XPRIZE can help to identify and accelerate possible solutions for COVID-19 as well as strategies to keep people safe while mitigating for a back to normal world. Our hope now is to implement the methodology and technology identified via this challenge into emergency response plans for local governments worldwide, utilizing artificial intelligence to better protect everyone – from the most vulnerable in our society to the most essential workers – against future pandemics.”
“We salute the ingenuity and dedication of the two winning teams of the Pandemic Response Challenge, VALENCIA IA4COVID19 and JSI vs COVID, and thank all who participated in this global competition,” said Brian Humphries, CEO of Cognizant. “It’s amazing what can happen when you bring together creative minds in data science, computer programming, machine learning, and epidemiology. Their data-driven, AI-based models will help policy makers and health officials safely restart economies and learn how to harness these technologies to tackle future public health crises.”
Contestants’ AI models were evaluated by an independent judging panel comprising academics, pandemic response specialists, AI experts, and epidemiologists, among others. Both grand prize-winning teams succeeded in creating effective models and meeting judging criteria that included both quantitative metrics and qualitative factors such as:
- Actionability and Usability of the models in real-world settings;
- Inclusivity and Fairness, which assessed how the models take into account particularly vulnerable groups;
- Collaborative Contributions that awarded teams who created open source models or contributed data and models for the shared success of all;
- Innovation, which considered whether teams found innovative ways to extend the scope of the Challenge
Complete judging criteria and Challenge guidelines are available on the XPRIZE website.
VALENCIA IA4COVID19 has collaborated with the Valencian government since March 2020 to leverage data science in the fight against COVID-19. Ultimately, the team’s winning model successfully forecasted epidemiological evolution through their use of AI and data science. JSI vs COVID worked to develop accurate predictors of COVID-19 infections using a combination of a SEIR epidemiological model and machine learning. Through the Challenge, both teams hope to achieve more accurate models for predicting the evolution of COVID-19 that can be used in their respective countries and beyond.
In addition to the two grand prize winners, eight other teams have received honorable mentions and will each receive $3,000 in AWS credits for cloud and compute services, courtesy of AWS, a supporting partner of the Challenge. These teams are:
- metis2020 (Los Angeles, Calif., US)
- mvsm (Berlin, Germany)
- CoronaSurveys (Madrid, Spain)
- Nixtamal AI (Mexico City, Mexico)
- Shanvi (San Diego, Calif., US)
- Kangaroos (Ultimo, Australia)
- ADVANCE4COVID (Rochester, NY, US)
- Nebraska team (Omaha, Neb., US)
All teams competing in the Pandemic Response Challenge used Cognizant’s foundational research and Evolutionary AI™ modeling as a baseline, building out their models using data compiled by the Oxford COVID-19 Government response tracker (based at Oxford University’s Blavatnik School of Government). The Pandemic Response Challenge was first launched in November 2020, and comprised two phases:
- Phase 1, concluded in January 2021: Contestants analyzed local COVID-19 data, existing intervention strategies, and common mitigation policies to develop and test prediction models capable of anticipating global infection spikes.
- Phase 2, concluded in February 2021: Contestants developed a “prescriptor ” model, which could suggest realistic intervention plans for reopening global economies while minimizing the number of COVID-19 cases and the cost of deploying intervention plans.
To facilitate development of their proposed solutions, teams were offered free cloud and computing services from AWS.
The COVID-19 pandemic has prompted a vast spectrum of unprecedented government and community interventions. The Pandemic Response Challenge used the most advanced AI technology, coupled with some of the most creative minds in the fields of data science, computer programming, machine learning, and more, to jumpstart new strategies for effectively reopening societies and restarting economies safely for everyone – as well as test scenarios that might be applied going forward.
Moving forward, XPRIZE and Cognizant, along with International Telecommunication Union (ITU), are expanding these efforts beyond the scope of this competition to one of a public platform and ecosystem that encourages the convening of AI and data while enabling the contributions of experts and thought leaders of the global community of public health. Details of the public platform will be announced soon. Those interested in joining and contributing to these efforts are encouraged to contact XPRIZE at pandemicresponse@xprize.org .
Learn more by watching this film explaining the Pandemic Response Challenge .
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100M XPRIZE Carbon Removal, $20 Million NRG COSIA Carbon XPRIZE, $15M XPRIZE Feed the Next Billion, $10 Million XPRIZE Rainforest, $10 Million ANA Avatar XPRIZE, $6 Million XPRIZE Rapid COVID Testing, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling, and $500K Pandemic Response Challenge. For more information, visit xprize.org.
About COGNIZANT
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005419/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
